Company Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.
The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.
It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder.
The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories.
The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jun 19, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 267 |
| CEO | Michael Raab |
Contact Details
Address: 400 Fifth Avenue, Suite 210 Waltham, Massachusetts 02451 United States | |
| Phone | 510 745 1700 |
| Website | ardelyx.com |
Stock Details
| Ticker Symbol | ARDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001437402 |
| CUSIP Number | 039697107 |
| ISIN Number | US0396971071 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael G. Raab | President, Chief Executive Officer and Director |
| Elizabeth A. Grammer Esq. | Chief Legal and Administrative Officer and Secretary |
| Dr. Laura A. Williams M.D., M.P.H. | Chief Medical Officer |
| Justin A. Renz CPA, MBA | Chief Financial and Operations Officer |
| Robert Felsch | Senior Vice President of Finance and Chief Accounting Officer |
| Caitlin Lowie | Vice President of Corporate Communications and Investor Relations |
| Mike Kelliher | Executive Vice President of Corporate Development and Strategy |
| Charon Spencer Sr. | Chief Human Resources Officer |
| David P. Rosenbaum | Chief Development Officer |
| Robert C. Blanks | Chief Regulatory Affairs and Quality Assurance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 144 | Filing |
| Nov 5, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 31, 2024 | 10-Q | Quarterly Report |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 28, 2024 | 144 | Filing |
| Oct 11, 2024 | 144 | Filing |
| Oct 9, 2024 | 8-K | Current Report |
| Sep 27, 2024 | 144 | Filing |